APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugates for Tumors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antibody-drug Conjugates for Tumors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025195 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugates for Tumors Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugates for Tumors Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugates for Tumors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugates for Tumors Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugates for Tumors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Antibody-drug Conjugates for Tumors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antibody-drug Conjugates for Tumors include Takeda, RemeGen, Roche（Genentech）, Rakuten Medical, Gilead Sciences, Pfizer（Seagen), GSK, Daiichi Sankyo and AbbVie(ImmunoGen), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antibody-drug Conjugates for Tumors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-drug Conjugates for Tumors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-drug Conjugates for Tumors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antibody-drug Conjugates for Tumors market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibody-drug Conjugates for Tumors Segment by Company

Takeda

RemeGen

Roche（Genentech）

Rakuten Medical

Gilead Sciences

Pfizer（Seagen)

GSK

Daiichi Sankyo

AbbVie(ImmunoGen)

AstraZeneca

ADC Therapeutics

Antibody-drug Conjugates for Tumors Segment by Type

DNA Damaging Drugs

Tubulin Inhibitors

Other

Antibody-drug Conjugates for Tumors Segment by Application

Hematological Tumors

Solid Tumors

Antibody-drug Conjugates for Tumors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugates for Tumors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugates for Tumors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugates for Tumors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antibody-drug Conjugates for Tumors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody-drug Conjugates for Tumors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antibody-drug Conjugates for Tumors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antibody-drug Conjugates for Tumors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antibody-drug Conjugates for Tumors Industry Trends Table 2. Antibody-drug Conjugates for Tumors Industry Drivers Table 3. Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges Table 4. Antibody-drug Conjugates for Tumors Industry Restraints Table 5. Global Antibody-drug Conjugates for Tumors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antibody-drug Conjugates for Tumors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers Table 9. Global Antibody-drug Conjugates for Tumors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antibody-drug Conjugates for Tumors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antibody-drug Conjugates for Tumors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antibody-drug Conjugates for Tumors Manufacturers, Product Type & Application Table 13. Global Antibody-drug Conjugates for Tumors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antibody-drug Conjugates for Tumors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of DNA Damaging Drugs Table 17. Major Manufacturers of Tubulin Inhibitors Table 18. Major Manufacturers of Other Table 19. Global Antibody-drug Conjugates for Tumors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 21. Global Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 22. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2026) Table 23. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2027-2032) Table 24. Global Antibody-drug Conjugates for Tumors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (K Units) Table 26. Global Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (K Units) Table 27. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2026) Table 28. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hematological Tumors Table 30. Major Manufacturers of Solid Tumors Table 31. Global Antibody-drug Conjugates for Tumors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 33. Global Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 34. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2026) Table 35. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2027-2032) Table 36. Global Antibody-drug Conjugates for Tumors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (K Units) Table 38. Global Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (K Units) Table 39. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2026) Table 40. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2027-2032) Table 41. Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2026) & (K Units) Table 43. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021-2026) Table 44. Global Antibody-drug Conjugates for Tumors Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Antibody-drug Conjugates for Tumors Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 48. North America Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 49. Europe Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 51. Europe Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 58. Global Antibody-drug Conjugates for Tumors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Antibody-drug Conjugates for Tumors Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Antibody-drug Conjugates for Tumors Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2026) Table 62. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Takeda Antibody-drug Conjugates for Tumors Product Portfolio Table 67. Takeda Recent Development Table 68. RemeGen Company Information Table 69. RemeGen Business Overview Table 70. RemeGen Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. RemeGen Antibody-drug Conjugates for Tumors Product Portfolio Table 72. RemeGen Recent Development Table 73. Roche（Genentech） Company Information Table 74. Roche（Genentech） Business Overview Table 75. Roche（Genentech） Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio Table 77. Roche（Genentech） Recent Development Table 78. Rakuten Medical Company Information Table 79. Rakuten Medical Business Overview Table 80. Rakuten Medical Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio Table 82. Rakuten Medical Recent Development Table 83. Gilead Sciences Company Information Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio Table 87. Gilead Sciences Recent Development Table 88. Pfizer（Seagen) Company Information Table 89. Pfizer（Seagen) Business Overview Table 90. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio Table 92. Pfizer（Seagen) Recent Development Table 93. GSK Company Information Table 94. GSK Business Overview Table 95. GSK Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. GSK Antibody-drug Conjugates for Tumors Product Portfolio Table 97. GSK Recent Development Table 98. Daiichi Sankyo Company Information Table 99. Daiichi Sankyo Business Overview Table 100. Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio Table 102. Daiichi Sankyo Recent Development Table 103. AbbVie(ImmunoGen) Company Information Table 104. AbbVie(ImmunoGen) Business Overview Table 105. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio Table 107. AbbVie(ImmunoGen) Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio Table 112. AstraZeneca Recent Development Table 113. ADC Therapeutics Company Information Table 114. ADC Therapeutics Business Overview Table 115. ADC Therapeutics Antibody-drug Conjugates for Tumors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio Table 117. ADC Therapeutics Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Antibody-drug Conjugates for Tumors Distributors List Table 121. Antibody-drug Conjugates for Tumors Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Antibody-drug Conjugates for Tumors Product Image Figure 2. Global Antibody-drug Conjugates for Tumors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-drug Conjugates for Tumors Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody-drug Conjugates for Tumors Sales (2021-2032) & (K Units) Figure 5. Global Antibody-drug Conjugates for Tumors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antibody-drug Conjugates for Tumors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. DNA Damaging Drugs Image Figure 9. Tubulin Inhibitors Image Figure 10. Other Image Figure 11. Global Antibody-drug Conjugates for Tumors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antibody-drug Conjugates for Tumors Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2032) Figure 14. Global Antibody-drug Conjugates for Tumors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Antibody-drug Conjugates for Tumors Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2032) Figure 17. Hematological Tumors Image Figure 18. Solid Tumors Image Figure 19. Global Antibody-drug Conjugates for Tumors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Antibody-drug Conjugates for Tumors Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2032) Figure 22. Global Antibody-drug Conjugates for Tumors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Antibody-drug Conjugates for Tumors Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2032) Figure 25. North America Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021-2032) Figure 27. U.S. Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021-2032) Figure 32. Germany Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021-2032) Figure 39. China Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021-2032) Figure 47. Brazil Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Antibody-drug Conjugates for Tumors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Antibody-drug Conjugates for Tumors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Figure 58. North America Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Figure 60. Europe Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antibody-drug Conjugates for Tumors Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Antibody-drug Conjugates for Tumors Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Damaging Drugs
  • Tubulin Inhibitors
  • Other
Applications
  • Hematological Tumors
  • Solid Tumors
Companies covered
  • Takeda
  • RemeGen
  • Roche（Genentech）
  • Rakuten Medical
  • Gilead Sciences
  • Pfizer（Seagen)
  • GSK
  • Daiichi Sankyo
  • AbbVie(ImmunoGen)
  • AstraZeneca
  • ADC Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody-drug Conjugates for Tumors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody-drug Conjugates for Tumors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antibody-drug Conjugates for Tumors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antibody-drug Conjugates for Tumors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antibody-drug Conjugates for Tumors Market Dynamics
  1. 2.1 Antibody-drug Conjugates for Tumors Industry Trends
  2. 2.2 Antibody-drug Conjugates for Tumors Industry Drivers
  3. 2.3 Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugates for Tumors Industry Restraints
3 Antibody-drug Conjugates for Tumors Market by Manufacturers
  1. 3.1 Global Antibody-drug Conjugates for Tumors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antibody-drug Conjugates for Tumors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antibody-drug Conjugates for Tumors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antibody-drug Conjugates for Tumors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antibody-drug Conjugates for Tumors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antibody-drug Conjugates for Tumors Manufacturers, Product Type & Application
  7. 3.7 Global Antibody-drug Conjugates for Tumors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antibody-drug Conjugates for Tumors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antibody-drug Conjugates for Tumors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antibody-drug Conjugates for Tumors Tier 1, Tier 2, and Tier 3
4 Antibody-drug Conjugates for Tumors Market by Type
  1. 4.1 Antibody-drug Conjugates for Tumors Type Introduction
  2. 4.1.1 DNA Damaging Drugs
  3. 4.1.2 Tubulin Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Antibody-drug Conjugates for Tumors Sales by Type
  6. 4.2.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
  8. 4.2.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2032)
  9. 4.3 Global Antibody-drug Conjugates for Tumors Revenue by Type
  10. 4.3.1 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
  12. 4.3.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2032)
5 Antibody-drug Conjugates for Tumors Market by Application
  1. 5.1 Antibody-drug Conjugates for Tumors Application Introduction
  2. 5.1.1 Hematological Tumors
  3. 5.1.2 Solid Tumors
  4. 5.2 Global Antibody-drug Conjugates for Tumors Sales by Application
  5. 5.2.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
  7. 5.2.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2032)
  8. 5.3 Global Antibody-drug Conjugates for Tumors Revenue by Application
  9. 5.3.1 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
  11. 5.3.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2032)
6 Global Antibody-drug Conjugates for Tumors Sales by Region
  1. 6.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2032)
  3. 6.2.1 Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2026)
  4. 6.2.2 Global Antibody-drug Conjugates for Tumors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antibody-drug Conjugates for Tumors Revenue by Region
  1. 7.1 Global Antibody-drug Conjugates for Tumors Revenue by Region
  2. 7.1.1 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antibody-drug Conjugates for Tumors Revenue by Region (2021-2026)
  4. 7.1.3 Global Antibody-drug Conjugates for Tumors Revenue by Region (2027-2032)
  5. 7.1.4 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antibody-drug Conjugates for Tumors Revenue (2021-2032)
  8. 7.2.2 North America Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antibody-drug Conjugates for Tumors Revenue (2021-2032)
  11. 7.3.2 Europe Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antibody-drug Conjugates for Tumors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antibody-drug Conjugates for Tumors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antibody-drug Conjugates for Tumors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Antibody-drug Conjugates for Tumors Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 RemeGen
  8. 8.2.1 RemeGen Company Information
  9. 8.2.2 RemeGen Business Overview
  10. 8.2.3 RemeGen Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 RemeGen Antibody-drug Conjugates for Tumors Product Portfolio
  12. 8.2.5 RemeGen Recent Developments
  13. 8.3 Roche（Genentech）
  14. 8.3.1 Roche（Genentech） Company Information
  15. 8.3.2 Roche（Genentech） Business Overview
  16. 8.3.3 Roche（Genentech） Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio
  18. 8.3.5 Roche（Genentech） Recent Developments
  19. 8.4 Rakuten Medical
  20. 8.4.1 Rakuten Medical Company Information
  21. 8.4.2 Rakuten Medical Business Overview
  22. 8.4.3 Rakuten Medical Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio
  24. 8.4.5 Rakuten Medical Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 Pfizer（Seagen)
  32. 8.6.1 Pfizer（Seagen) Company Information
  33. 8.6.2 Pfizer（Seagen) Business Overview
  34. 8.6.3 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio
  36. 8.6.5 Pfizer（Seagen) Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GSK Antibody-drug Conjugates for Tumors Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 AbbVie(ImmunoGen)
  50. 8.9.1 AbbVie(ImmunoGen) Company Information
  51. 8.9.2 AbbVie(ImmunoGen) Business Overview
  52. 8.9.3 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio
  54. 8.9.5 AbbVie(ImmunoGen) Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 ADC Therapeutics
  62. 8.11.1 ADC Therapeutics Company Information
  63. 8.11.2 ADC Therapeutics Business Overview
  64. 8.11.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio
  66. 8.11.5 ADC Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antibody-drug Conjugates for Tumors Value Chain Analysis
  2. 9.1.1 Antibody-drug Conjugates for Tumors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antibody-drug Conjugates for Tumors Production Mode & Process
  6. 9.2 Antibody-drug Conjugates for Tumors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antibody-drug Conjugates for Tumors Distributors
  9. 9.2.3 Antibody-drug Conjugates for Tumors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst